Realizing the Potential of Telemedicine in China, Part 1: Protecting Your IP

30 September 2014 Health Care Law Today Blog
Authors: Nathaniel M. Lacktman Tianran Yan

This post is the second in Foley’s blogs on China telemedicine and the first in the blog series, “Realizing the Potential of Telemedicine in China,” meant to address top issues facing U.S. companies looking to enter the Chinese telemedicine market. We hope to expand the series to include additional issues.

At a Glance

  • Companies expanding into China must register IP assets separately in China; registrations must be filed in English and Chinese
  • Contracts in China are used to manage expectations; to avoid getting lost in translation, they should be drawn up in English and Chinese
  • Thorough due diligence in China is critical if U.S. companies are to avoid being “home turfed.”

Telemedicine device manufacturers and software developers face different challenges related to IP protection when expanding into China, including when it comes to trade secret protection, IP asset registration, contracts, and due diligence.

Asset Registration

To start, U.S. companies must change their approach to IP asset registration, as registration in the United States is insufficient to ensure protection abroad. Patents, trademarks, copyrights, and other assets registered in the United States must also be registered separately with Chinese agencies, and the registrations must be completed in English and Chinese, to avoid ambiguity and leave them open to interpretation by Chinese courts. For U.S. suppliers of telemedicine devices and software, it would be wise to file patent applications and/or copyright registrations in China as early as possible to deter competitors from copying their proprietary devices and software.

Meeting With a Potential Partner

For U.S. telemedicine companies that heavily rely on trade secrets to protect their proprietary technical and business information, they should consider taking various precautions before, during, and after meeting with a potential Chinese partner.  For example, before meeting with the Chinese partner, the U.S. company can file a U.S. provisional patent application directed to their proprietary technical information that they have considered as trade secret.  The provisional application does not publish and gives the U.S. company an option to file a regular patent application in many countries, including China, within one year.  If, within that year, the U.S. company found that the Chinese partner has acted to disclose such proprietary technical information without authorization, thereby disclosing aspects of the trade secret, the U.S. company will still be able to avail itself of some level of protection of such proprietary technical information in the form of a patent application.

Of course, highly proprietary information should not be shared before proper due diligence has been undertaken on the party receiving access to such information in order to “seal the deal” with a US telemedicine services company, including a company offering devices and/or software.  Even then, where sharing can be limited (i.e., summaries of proprietary technology documentation), risk of significant financial and other harms to the US company can be reduced.

During the meeting and contract negotiation with the Chinese partner, the U.S. company should consider asking the Chinese partner to sign an acknowledgement and description of all proprietary information disclosed by the U.S. company.  A three-way confidentiality agreement can also be executed between the U.S. company, the Chinese partner, and the Chinese partner’s relevant employees to maximize protection of the U.S. company’s trade secrets.

Contracts

In addition, U.S. and Chinese companies view the purpose of contracts differently. For example, in China, contracts are generally drawn up to manage expectations (cooperation agreements), rather than as a tool to be used in litigation, should parties not live up to the contract, as they are in the United States. That said, it is critical that if a U.S. company is to effectively manage expectations, all contracts should be drawn up separately in both English and Chinese, to ensure that nothing is lost in translation and in the event of an issue, the interpretation of an English contract is not left up to a Chinese court.

Due diligence in China is just as critical, if not more so, than due diligence in the United States. Understand the entities you are doing business with, both inside and out. By spending a bit more on front-end due diligence, U.S. companies can avoid being “home turfed,” finding themselves stuck with contracts with Chinese partners that are unenforceable.

Furthermore, after the meeting, due diligence investigation, and the execution of contracts, the U.S. companies should continue monitoring the situation to ensure that access to its trade secret is properly limited and that precautions are taken when a relevant employee resign from the Chinese partner or becomes an independent contractor.  If the precautionary steps discussed herein are properly taken, a U.S. telemedicine company could place itself in a good position to safeguard its trade secrets in China.     

Are you interested in learning more about telemedicine in China? Foley offers two opportunities to get up to speed with the latest developments:

English Translations of China’s NHFPC Opinions (Issued August 2014)

Members of Foley’s Telemedicine and China Practices have completed English-language translations of an Interpretation and associated Opinion on the Promotion of Medical Institution Telemedicine Services, issued in August 2014 by The National Health and Family Planning Commission of the People’s Republic of China.

The translations are available online.

Upcoming Complimentary Web Conference on Telemedicine: Doing Business in China

On Monday, October 6, Foley Partners Nate Lacktman and Tad Ferris will be presenting Telemedicine: Doing Business in China, a 60-minute, complimentary Web conference addressing:

  • The current landscape and business opportunities related to devices, software, and service providers for telemedicine companies and hospitals seeking to do business in China
  • A look at the recent China telemedicine guidance and opinions issued in August 2014, against the backdrop of historical telemedicine rules
  • Challenges and best practices regarding telemedicine business in China, including tackling IP and trade secret protection
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

Cryptocurrency in China is like BIG BROTHER in 1984!
20 October 2019
Internet, IT & e-Discovery Blog
California Governor Signs New Telehealth Insurance Law
18 October 2019
Health Care Law Today
Continued Increase in E-Commerce and Online Ordering Changes Landscape of Urban Transportation
17 October 2019
Dashboard Insights
CMS Proposes Revisions to Stark Law
16 October 2019
Health Care Law Today
PATH Summit 2019
18-20 December 2019
Arlington, VA
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.